المؤلفون: Wang T; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Liu P; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Xu L; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Gao L; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Ni X; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Tang G; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Chen L; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Chen J; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Wang L; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Wang Y; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Fu W; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Yue W; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Liu N; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Li R; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China., Lu G; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. lovelugh@163.com., Luo Y; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. 122158553@qq.com., Yang J; Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. chyangjianmin@163.com.

المصدر: Annals of hematology [Ann Hematol] 2024 Feb; Vol. 103 (2), pp. 575-582. Date of Electronic Publication: 2023 Nov 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/methods , Lymphoma, Large B-Cell, Diffuse*/therapy, Humans ; Carmustine/adverse effects ; Melphalan/adverse effects ; Etoposide/adverse effects ; Semustine ; Cohort Studies ; Propensity Score ; Transplantation, Autologous/methods ; Neoplasm Recurrence, Local ; Cyclophosphamide/adverse effects ; Cytarabine/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Zhang L; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; First Affiliated Hospital of Soochow University, Department of Ultrasound, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Yang H; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Qian C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Zhou J; The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Department of Hematology, Shenzhen, Guangdong, People's Republic of China., Zhu Q; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Jiang Y; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Liu S; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Chen X; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Xu T; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Qu C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Li C; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Jin Z; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China., Chu J; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China., Zhang X; The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Department of Hematology, Shenzhen, Guangdong, People's Republic of China., Wu D; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China., Huang H; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, Jiangsu, People's Republic of China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, People's Republic of China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, People's Republic of China.

المصدر: Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 404-411.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/adverse effects , Lymphoma*/therapy, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/adverse effects ; Etoposide/adverse effects ; Humans ; Melphalan/adverse effects ; Retrospective Studies ; Semustine ; Stem Cell Transplantation ; Transplantation Conditioning/adverse effects ; Transplantation, Autologous

المؤلفون: Lu G; Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China., Chen L; Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China., Wu S; Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China., Feng Y; College of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China., Lin T; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.

المصدر: Disease markers [Dis Markers] 2020 May 11; Vol. 2020, pp. 8974793. Date of Electronic Publication: 2020 May 11 (Print Publication: 2020).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 8604127 Publication Model: eCollection Cited Medium: Internet ISSN: 1875-8630 (Electronic) Linking ISSN: 02780240 NLM ISO Abbreviation: Dis Markers Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Esophageal Neoplasms/*drug therapy , Esophageal Neoplasms/*immunology , Lymphocytes, Tumor-Infiltrating/*pathology , Tumor Microenvironment/*immunology, Adult ; Algorithms ; Cell Count ; Databases, Factual ; Dendritic Cells/drug effects ; Dendritic Cells/immunology ; Dendritic Cells/pathology ; Esophageal Neoplasms/diagnosis ; Esophageal Neoplasms/mortality ; Female ; Gene Expression ; Humans ; Lymph Nodes/drug effects ; Lymph Nodes/immunology ; Lymph Nodes/pathology ; Lymphocytes, Tumor-Infiltrating/drug effects ; Lymphocytes, Tumor-Infiltrating/immunology ; Male ; Mast Cells/drug effects ; Mast Cells/immunology ; Mast Cells/pathology ; Middle Aged ; Monocytes/drug effects ; Monocytes/immunology ; Monocytes/pathology ; Neoplasm Staging ; Plasma Cells/drug effects ; Plasma Cells/immunology ; Plasma Cells/pathology ; Prognosis ; Receptors, LDL/genetics ; Receptors, LDL/immunology ; Regression Analysis ; Semustine/therapeutic use ; Sirolimus/therapeutic use ; Survival Analysis ; T Follicular Helper Cells/drug effects ; T Follicular Helper Cells/immunology ; T Follicular Helper Cells/pathology ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/genetics ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/immunology

المؤلفون: Yu ZP; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Ding JH; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Sun AN; Hematology Division, Soochow University Affiliated No 1 People's Hospital, Suzhou, China., Chen BA; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Ge Z; Department of Hematology (Key Department of Jiangsu Medicine), Zhong Da Hospital, Southeast University, Nanjing, China., Wu DP; Hematology Division, Soochow University Affiliated No 1 People's Hospital, Suzhou, China.

المصدر: Stem cells and development [Stem Cells Dev] 2019 Oct 15; Vol. 28 (20), pp. 1376-1383. Date of Electronic Publication: 2019 Sep 26.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101197107 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8534 (Electronic) Linking ISSN: 15473287 NLM ISO Abbreviation: Stem Cells Dev Subsets: MEDLINE

مواضيع طبية MeSH: Cord Blood Stem Cell Transplantation* , Immune Reconstitution*, Anemia, Aplastic/*drug therapy , Leukemia, Myeloid, Acute/*drug therapy , Myelodysplastic Syndromes/*drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy , Primary Immunodeficiency Diseases/*drug therapy , Transplantation Conditioning/*methods, Adult ; Anemia, Aplastic/immunology ; Anemia, Aplastic/mortality ; Anemia, Aplastic/pathology ; Antilymphocyte Serum/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Busulfan/administration & dosage ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Female ; Graft Survival ; Graft vs Host Disease/physiopathology ; Graft vs Host Disease/prevention & control ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Immunosuppressive Agents/therapeutic use ; Leukemia, Myeloid, Acute/immunology ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Myelodysplastic Syndromes/immunology ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/pathology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Primary Immunodeficiency Diseases/immunology ; Primary Immunodeficiency Diseases/mortality ; Primary Immunodeficiency Diseases/pathology ; Semustine/administration & dosage ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Unrelated Donors ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives

المؤلفون: Sun J; Department of Neurosurgery, General Hospital, Tianjin Medical University, Tianjin, China., Yang XJ, Yang SY

المصدر: Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2013 Jan 15; Vol. 93 (3), pp. 165-8.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Zhonghua yi xue hui Country of Publication: China NLM ID: 7511141 Publication Model: Print Cited Medium: Print ISSN: 0376-2491 (Print) Linking ISSN: 03762491 NLM ISO Abbreviation: Zhonghua Yi Xue Za Zhi Subsets: MEDLINE

مواضيع طبية MeSH: Semustine*/adverse effects , Semustine*/therapeutic use, Dacarbazine/*analogs & derivatives , Glioma/*drug therapy, Adult ; Astrocytoma/drug therapy ; Dacarbazine/adverse effects ; Dacarbazine/therapeutic use ; Female ; Glioblastoma/drug therapy ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Temozolomide

مؤلفون مشاركون: National Toxicology Program

المصدر: Report on carcinogens : carcinogen profiles [Rep Carcinog] 2011; Vol. 12, pp. 327-8.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: National Institute of Environmental Health Sciences, [2000- Country of Publication: United States NLM ID: 101157309 Publication Model: Print Cited Medium: Internet ISSN: 1551-8280 (Electronic) Linking ISSN: 15518272 NLM ISO Abbreviation: Rep Carcinog Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Alkylating/*toxicity , Carcinogens, Environmental/*toxicity , Semustine/*toxicity, Animals ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/chemistry ; Carcinogenicity Tests ; Carcinogens, Environmental/chemistry ; Carcinogens, Environmental/poisoning ; Humans ; Mice ; Molecular Structure ; Occupational Exposure/adverse effects ; Rats ; Semustine/adverse effects ; Semustine/chemistry

المؤلفون: Huang H; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. huanghaiwen@suda.edu.cn.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. huanghaiwen@suda.edu.cn., Zhang L; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China., Jiang Y; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China., Liu S; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China., Jin Z; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China., Chen J; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China., Xiao X; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China., Ruan J; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. jruan@med.cornell.edu.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. jruan@med.cornell.edu.; Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York-Presbyterian Hospital, 1305 York Ave., 7th Fl, New York, NY, USA. jruan@med.cornell.edu., Zhang X; Department of Hematology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, No. 1017 Dongmen North Road, Shenzhen, 518020, Guangdong, China. zhangxinyou0518@sina.com., Wu D; Department of Hematology, The First Affiliated Hospital of Soochow University, No. 188. Shi Zi Street, Suzhou, 215006, China. wudepei@medmail.com.cn.; Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, Suzhou, Jiangsu, China. wudepei@medmail.com.cn.

المصدر: Annals of hematology [Ann Hematol] 2019 May; Vol. 98 (5), pp. 1259-1266. Date of Electronic Publication: 2019 Jan 12.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation* , Transplantation Conditioning*, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Lymphoma/*mortality , Lymphoma/*therapy, Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Autografts ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Disease-Free Survival ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Female ; Humans ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Middle Aged ; Semustine/administration & dosage ; Semustine/adverse effects ; Survival Rate

SCR Protocol: BUCY-2 protocol

المساهمون: Pant, AB^Aff1

المصدر: Dictionary of Toxicology. :914-915

المصدر: Report on carcinogens : carcinogen profiles [Rep Carcinog] 2004; Vol. 11, pp. III53.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: National Institute of Environmental Health Sciences, [2000- Country of Publication: United States NLM ID: 101157309 Publication Model: Print Cited Medium: Print ISSN: 1551-8272 (Print) Linking ISSN: 15518272 NLM ISO Abbreviation: Rep Carcinog Subsets: MEDLINE

مواضيع طبية MeSH: Semustine/*adverse effects, Animals ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/chemical synthesis ; Antineoplastic Agents, Alkylating/chemistry ; Antineoplastic Agents, Alkylating/toxicity ; Carcinogenicity Tests ; Guidelines as Topic ; Humans ; Mice ; Models, Biological ; Occupational Exposure/adverse effects ; Occupational Exposure/legislation & jurisprudence ; Rats ; Semustine/chemical synthesis ; Semustine/chemistry ; Semustine/toxicity

المؤلفون: Ma X; Department of Radiation Oncology, Fudan University, Shanghai, China., Guo Y, Pang Z, Wang B, Lu H, Gu YJ, Guo X

المصدر: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2009 Dec; Vol. 93 (3), pp. 492-7. Date of Electronic Publication: 2009 Sep 24.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Lymphoma, Extranodal NK-T-Cell/*drug therapy , Nose Neoplasms/*drug therapy , Semustine/*administration & dosage, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Epirubicin/administration & dosage ; Epirubicin/adverse effects ; Female ; Humans ; Lymphoma, Extranodal NK-T-Cell/mortality ; Lymphoma, Extranodal NK-T-Cell/radiotherapy ; Male ; Middle Aged ; Neoplasm Invasiveness ; Nose Neoplasms/radiotherapy ; Pharyngeal Neoplasms/drug therapy ; Pharyngeal Neoplasms/radiotherapy ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Prognosis ; Radiation Injuries ; Semustine/adverse effects ; Survival Rate ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Young Adult

SCR Protocol: CEOP protocol 1